OPERA-01: a phase III study of palazestrant for ER+, HER2– advanced breast cancer after CDK4/6 inhibitor therapy
- DOI
- 10.1080/14796694.2025.2608863
- Published
- 2025-12-29
- Container
- Future Oncology
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2025.2608863,
title = {OPERA-01: a phase III study of palazestrant for ER+, HER2– advanced breast cancer after CDK4/6 inhibitor therapy},
author = {Barbara Pistilli and Meritxell Bellet Ezquerra and Lucia Del Mastro and Joohyuk Sohn and Peter Schmid and Jane Meisel and Arlene Chan and Lianqing Zheng and Elisabeth de Kermadec and Heather McArthur},
year = {2025},
journal = {Future Oncology},
doi = {10.1080/14796694.2025.2608863},
url = {https://doi.org/10.1080/14796694.2025.2608863}
}RIS
TY - JOUR TI - OPERA-01: a phase III study of palazestrant for ER+, HER2– advanced breast cancer after CDK4/6 inhibitor therapy AU - Barbara Pistilli AU - Meritxell Bellet Ezquerra AU - Lucia Del Mastro AU - Joohyuk Sohn AU - Peter Schmid AU - Jane Meisel AU - Arlene Chan AU - Lianqing Zheng AU - Elisabeth de Kermadec AU - Heather McArthur PY - 2025 JO - Future Oncology DO - 10.1080/14796694.2025.2608863 UR - https://doi.org/10.1080/14796694.2025.2608863 ER -
APA
Pistilli, B., Ezquerra, M. B., Mastro, L. D., Sohn, J., Schmid, P., Meisel, J., Chan, A., Zheng, L., Kermadec, E. D., & McArthur, H. (2025). OPERA-01: a phase III study of palazestrant for ER+, HER2– advanced breast cancer after CDK4/6 inhibitor therapy. Future Oncology. https://doi.org/10.1080/14796694.2025.2608863
Source records
- crossref · retrieved 2026-09-26T23:03:33.529Z